Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals.

Ryom L, Mocroft A, Kirk O, Reiss P, Ross M, Smith C, Moranne O, Morlat P, Fux CA, Sabin C, Phillips A, Law M, Lundgren JD; D:A:D study group.

AIDS. 2017 Jun 1;31(9):1261-1270. doi: 10.1097/QAD.0000000000001464.

PMID:
28492392
2.

Predictors of eGFR progression, stabilisation or improvement after chronic renal impairment in HIV-positive individuals.

Ryom L, Mocroft A, Kirk O, Reiss P, Ross M, Smith C, Moranne O, Morlat P, Fux CA, Sabin C, Phillips A, Law M, Lundgren JD; D:A:D study group.

AIDS. 2017 Mar 28. doi: 10.1097/QAD.0000000000001464. [Epub ahead of print]

PMID:
28353536
3.

The benefits and risks of PrEP and kidney function.

Mocroft A, Ryom L.

Lancet HIV. 2016 Nov;3(11):e501-e502. doi: 10.1016/S2352-3018(16)30148-5. Epub 2016 Aug 31. No abstract available.

PMID:
27658871
4.

Renal Impairment and Cardiovascular Disease in HIV-Positive Individuals: The D:A:D Study.

Ryom L, Lundgren JD, Ross M, Kirk O, Law M, Morlat P, Fontas E, Smit C, Fux CA, Hatleberg CI, de Wit S, Sabin CA, Mocroft A; D:A:D Study Group.

J Infect Dis. 2016 Oct 15;214(8):1212-20. doi: 10.1093/infdis/jiw342. Epub 2016 Aug 2.

PMID:
27485357
5.

Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments.

Achhra AC, Nugent M, Mocroft A, Ryom L, Wyatt CM.

Curr HIV/AIDS Rep. 2016 Jun;13(3):149-57. doi: 10.1007/s11904-016-0315-y. Review.

PMID:
27130284
6.

Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study.

Kamara DA, Smith C, Ryom L, Reiss P, Rickenbach M, Phillips A, Mocroft A, De Wit S, Law M, Monforte AD, Dabis F, Pradier C, Lundgren JD, Sabin C.

Antivir Ther. 2016;21(6):495-506. doi: 10.3851/IMP3051. Epub 2016 Apr 26.

PMID:
27114439
7.

Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.

Sabin CA, Reiss P, Ryom L, Phillips AN, Weber R, Law M, Fontas E, Mocroft A, de Wit S, Smith C, Dabis F, d'Arminio Monforte A, El-Sadr W, Lundgren JD; D:A:D Study Group.

BMC Med. 2016 Mar 31;14:61. doi: 10.1186/s12916-016-0588-4.

8.

Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals.

Hatleberg CI, Ryom L, El-Sadr W, Smith C, Weber R, Reiss P, Fontas E, Dabis F, Law M, Monforte Ad, De Wit S, Mocroft A, Phillips A, Lundgren JD, Sabin C; D:A:D Study Group.

AIDS. 2016 Jun 19;30(10):1583-96. doi: 10.1097/QAD.0000000000001076.

PMID:
26950315
9.

Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study.

Kovari H, Sabin CA, Ledergerber B, Ryom L, Reiss P, Law M, Pradier C, Dabis F, d'Arminio Monforte A, Smith C, de Wit S, Kirk O, Lundgren JD, Weber R.

Open Forum Infect Dis. 2016 Jan 21;3(1):ofw009. doi: 10.1093/ofid/ofw009. eCollection 2016 Jan.

10.

Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?

Boettiger DC, Sabin CA, Grulich A, Ryom L, Bonnet F, Reiss P, Monforte Ad, Kirk O, Phillips A, Bower M, Fätkenheuer G, Lundgren JD, Law M; Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group.

AIDS. 2016 Jun 19;30(10):1629-37. doi: 10.1097/QAD.0000000000001053.

11.

Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.

Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study.

Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17.

PMID:
26762990
12.

Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons.

Ryom L, Lundgren JD, De Wit S, Kovari H, Reiss P, Law M, El-Sadr W, Monforte AD, Mocroft A, Smith C, Fontas E, Dabis F, Phillips A, Sabin C; D:A:D Study Group.

AIDS. 2016 Jul 17;30(11):1731-43. doi: 10.1097/QAD.0000000000001018.

PMID:
26752282
13.

Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons.

Ryom L, Boesecke C, Gisler V, Manzardo C, Rockstroh JK, Puoti M, Furrer H, Miro JM, Gatell JM, Pozniak A, Behrens G, Battegay M, Lundgren JD; EACS Governing Board.

HIV Med. 2016 Feb;17(2):83-8. doi: 10.1111/hiv.12322. Epub 2015 Nov 8.

PMID:
26548563
14.

Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study.

Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, Smith CJ, d'Arminio Monforte A, Phillips A, Weber R, Lundgren J, Law MG; D:A:D Study Group.

HIV Med. 2016 Apr;17(4):255-68. doi: 10.1111/hiv.12294. Epub 2015 Jul 28.

PMID:
26216031
15.

An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study.

Friis-Møller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, De Wit S, Monforte AD, Kirk O, Fontas E, Sabin C, Phillips A, Lundgren J, Law M; D:A:D study group.

Eur J Prev Cardiol. 2016 Jan;23(2):214-23. doi: 10.1177/2047487315579291. Epub 2015 Apr 16.

PMID:
25882821
16.

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group.

PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar.

17.

Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study.

Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, de Wit S, D Arminio Monforte A, Furrer H, Pradier C, Lundgren J, Sabin C; D:A:D study group.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):568-77. doi: 10.1097/QAI.0000000000000523.

PMID:
25763785
18.

Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Achhra AC, Mocroft A, Ross MJ, Ryom L, Lucas GM, Furrer H, Neuhaus J, Somboonwit C, Kelly M, Gatell JM, Wyatt CM; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group.

HIV Med. 2015 Apr;16 Suppl 1:55-63. doi: 10.1111/hiv.12234.

19.

The prevalence and predictive value of dipstick urine protein in HIV-positive persons in Europe.

Mocroft A, Ryom L, Lapadula G, Reiss P, Blaxhult A, Furrer H, Kutsyna G, Gatell J, Begovac J, Kirk O, Lundgren J.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19561. doi: 10.7448/IAS.17.4.19561. eCollection 2014.

20.

Gender differences in HIV-positive persons in use of cardiovascular disease-related interventions: D:A:D study.

Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, de Wit S, Dabis F, Pradier C, Monforte Ad, Rickenbach M, Law M, Lundgren J, Sabin C.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19516. doi: 10.7448/IAS.17.4.19516. eCollection 2014.

Supplemental Content

Loading ...
Support Center